Mechanisms of Tamoxifen Resistance in the Treatment of Advanced Breast Cancer
- 1 January 1996
- journal article
- review article
- Published by Taylor & Francis in Acta Oncologica
- Vol. 35 (sup5) , 9-14
- https://doi.org/10.3109/02841869609083961
Abstract
Multiple mechanisms may render breast cancer cells resistant to treatment with the antiestrogen tamoxifen. This review describes changes in the estrogen receptor (ER) signaling pathway which may lead to tamoxifen resistance: change in uptake or metabolism of tamoxifen, loss of expression of ER, decreased expression of ER, expression of mutant or variant forms of ER, intact ER but loss of cofactors, ligand-independent ER activation, modification of the estrogen response element, altered post-receptor events. Non-ER related alterations are also mentioned.Keywords
This publication has 35 references indexed in Scilit:
- P-glycoprotein and resistance to tamoxifenThe Lancet, 1994
- Regulation of insulin-like growth factors by antiestrogenBreast Cancer Research and Treatment, 1994
- Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentrationThe Lancet, 1993
- Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients.Journal of Clinical Oncology, 1992
- Tamoxifen as an Agonist for Metastatic Breast CancerPublished by Springer Nature ,1990
- Human breast cancer in the athymic nude mouse: Cystostatic effects of long-term antiestrogen therapyEuropean Journal of Cancer and Clinical Oncology, 1987
- High-affinity anti-oestrogen binding site distinct from the oestrogen receptorNature, 1980
- Estrogen Control of Progesterone Receptor in Human Breast Cancer: Role of Estradiol and Antiestrogen*Endocrinology, 1978
- Tamoxifen in advanced breast cancerCancer Treatment Reviews, 1978
- Hormones in breast cancer: Update 1978Metabolism, 1978